Ghostwriting: The dirty little secret of medical publishing that just got bigger

PLoS Medicine

Volumn 6, Issue 9, 2009, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG INDUSTRY; EDITORIAL; HEALTH CARE; HORMONE SUBSTITUTION; MEDICAL RESEARCH; MEDICAL SCHOOL; PHYSICIAN; ARTICLE; ETHICS; HUMAN; PUBLICATION; PUBLISHING; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; DRUG INDUSTRY; EDITORIAL POLICIES; HUMANS; PERIODICALS AS TOPIC; PUBLISHING;

EID: 70349650421     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000156     Document Type: Editorial

References (12)

1. http://www.plosmedicine.org/static/ghostwriting.action.
2. Lea A (2003) Totelle manuscripts sign-off and review [E-mail]. Available: http://www.plos.org/ghostwriting/Exhibits2/CONSG204-014513. TIF. Accessed 19 August 2009.
3. The PLoS Medicine Editors (2009) An unbiased scientific record should be everyone's agenda. PLoS Med 6(2): e1000038. doi:10.1371/journal.pmed.1000038.
4. Sismondo S (2007) Ghost Management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4(9): e286. doi: 10.1371/journal.pmed.0040286.
5. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, et al. (2009) What should be done to tackle ghostwriting in the medical literature? PLoS Med 6(2): e1000023. doi:10.1371/journal.pmed.1000023.
6. Wager E (2007) Authors, ghosts, damned lies, and statisticians. PLoS Med 4(1): e34. doi:10.1371/journal.pmed.0040034.
7. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812.
8. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, et al. (2007) Ghost authorship in industry-initiated randomised trials. PLoS Med 4(1): e19. doi:10.1371/journal.pmed.0040019. (Pubitemid 46191820)
9. DeAngelis CD, Fontanarosa PB (2008) Impugning the integrity of medical science the adverse effects of industry influence. JAMA 299: 1833-1835.
10. WAME (2005) Ghost writing initiated by commercial companies. Available: http://www.wame.org/resources/policies#ghost. Accessed 19 August 2009.
11. Wager E, Field EA, Grossman L (2003) Good publication practice for pharmaceutical companies. Curr Med Res Opin 19: 149-154. Available: http://basic1.easily.co.uk/03100E/00605D/GPP.pdf. Accessed 19 August 2009. (Pubitemid 36612997)
12. ICMJE (2008) Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication: Byline authors. Available: http://www.icmje.org/#author. Accessed 19 August 2009.